MacroGenics, Inc. MGNX 深 沪
等待开盘 05-19 09:30:00 美东时间
4.35
+0.100
+2.35%
华盛通- 最 高4.56
- 今 开4.175
- 成交量 135.25万股
- 最 低 4.10
- 昨 收 4.25
- 总市值 2.76亿
- 52周最高 4.56
- 市盈率 静 --
- 换手率 2.13%
- 52周最低 1.185
- 委 比 -37.97%
- 总股本 6356.31万
- 历史最高 41.00
- 量 比 0.38
- 振 幅 10.82%
- 历史最低 0.9897
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Macrogenics Q1 EPS $(0.58) Beats $(0.65) Estimate, Sales $20.775M Beat $15.050M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 9.38 percent. This is a 10.77 percent increase over losses of $(0.65) per share from the
05-14 04:56
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock moved upwards by 79.4% to $12....
05-13 01:06
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.
05-12 18:05
美股夜盘 | 安博教育涨65.40%，Xos, Inc.涨30.69%
微宏控股涨-37.13%；沃氪医疗涨-36.22%；Power Solutions International, Inc.涨-35.77%
05-12 08:05
MacroGenics Enters Into Expanded Royalty Purchase Agreement With Sagard In Exchange For Capped Royalty Interest On Future Global Net Sales Of ZYNYZ
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it entered into an expanded
05-04 19:33
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.
04-20 21:49
MacroGenics Says FDA Removes Partial Clinical Hold On Phase 2 LINNET Study Of Lorigerlimab, Investigational, Bispecific DART Molecule That Targets PD-1 And CTLA-4
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers• On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a
04-09 04:32
美股牛股 | VYGR飙升21%，Q4亏损收窄及销售额超预期；Figure大涨超20%
VYGR飙升21%，Q4亏损收窄及销售额超预期；Figure大涨超20%，进军汽车贷款市场获华尔街唱多；Stagwell涨逾17%，引入AppLovin先进的移动广告平台>>
03-11 16:04
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
